Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2120-2129

  Dewdney, Summer B ^a   Rimel, B J ^a   Thaker, Premal H ^a   Thompson Jr , Dominic M ^b   Schmidt, Amy ^b   Huettner, Phyllis ^a   Mutch, David G ^a   Gao, Feng ^a   Goodfellow, Paul J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DNA; PROTEIN RPS6KA6; S6 KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME REACTIVATION; EPIGENETICS; FEMALE; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RPS6KA6 GENE; TUMOR SUPPRESSOR GENE; X CHROMOSOME LINKAGE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, X-LINKED; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 79954587371     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2668     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 2009;36:145-54.
3. Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 2008;68:6902-7.
4. Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol 2009;5:27-32.
5. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
6. Myers AP, Corson LB, Rossant J, Baker JC. Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol 2004;24:4255-66. (Pubitemid 41070997)
7. Lopez-Vicente L, Armengol G, Pons B, Coch L, Argelaguet E, Lleonart M, et al. Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin Cancer Res 2009;15:4546-53.
8. Thakur A, Rahman KW, Wu J, Bollig A, Biliran H, Lin X, et al. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol Cancer Res 2007;5:171-81. (Pubitemid 46423998)
9. Thakur A, Xu H, Wang Y, Bollig A, Biliran H, Liao JD. The role of X-linked genes in breast cancer. Breast Cancer Res Treat 2005;93:135-43. (Pubitemid 41396775)
10. Thakur A, Sun Y, Bollig A, Wu J, Biliran H, Banerjee S, et al. Antiinvasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin Cancer Res 2008;14:4427-36.
11. Lleonart ME, Vidal F, Gallardo D, Diaz-Fuertes M, Rojo F, Cuatrecasas M, et al. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol Rep 2006;16:603-8.
12. Dummler BA, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B, et al. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem 2005;280:13304-14. (Pubitemid 40517216)
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
14. Zighelboim I, Goodfellow PJ, Schmidt AP, Walls KC, Mallon MA, Mutch DG, et al. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clin Cancer Res 2007;13:2882-9. (Pubitemid 46849562)
15. Whitehead TD, Brownstein BH, Parry JJ, Thompson D, Cha BA, Moros EG, et al. Expression of the proto-oncogene Fos after exposure to radiofrequency radiation relevant to wireless communications. Radiat Res 2005;164:420-30. (Pubitemid 41368950)
16. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, et al. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 1994;54:499-505. (Pubitemid 24053192)
17. Niehof M, Borlak J. RSK4 and PAK5 are novel candidate genes in diabetic rat kidney and brain. Mol Pharmacol 2005;67:604-11. (Pubitemid 40365307)
18. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62. (Pubitemid 350059681)
19. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008;105:8713-7. (Pubitemid 351987745)
20. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91. (Pubitemid 46630943)
21. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 2007;98:652-8. (Pubitemid 46563440)
22. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5. (Pubitemid 41297230)
23. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 2003;9:2277-87. (Pubitemid 36687653)
24. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005;434:400-4. (Pubitemid 40469185)
25. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-32. (Pubitemid 43202662)
26. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.
27. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008;13:4258-75. (Pubitemid 351611599)
28. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007;43:2434-44. (Pubitemid 350001248)
29. Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24:1745-53. (Pubitemid 46622146)
30. Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007;25:2042-8. (Pubitemid 46972789)
31. Mackay HJ, Gallinger S, Tsao MS, McLachlin CM, Tu D, Keiser K, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 2010;46:1365-73.